Last reviewed · How we verify
NCT07022028: GUIMAUVE
Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis
trial in Myasthenia Gravis in 800 participants. Completed in 6 November 2024.
6 November 2024
Quick facts
| Lead sponsor | Poitiers University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 27 February 2024 |
| Primary completion | 6 November 2024 |
| Estimated completion | 6 November 2024 |
| Sites | 1 location across France |
Conditions studied
- Myasthenia Gravis — all drugs for Myasthenia Gravis →
- Guillain-Barre Syndrome — all drugs for Guillain-Barre Syndrome →
Sponsor
Poitiers University Hospital
Who can join
Eligibility, any sex, with Myasthenia Gravis or Guillain-Barre Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Guillain-Barré syndrome and myasthenia gravis are two neuromuscular diseases that are commonly managed in ICUs that may require different weaning protocols. To date, no study has compared weaning modalities from mechanical ventilation in patients with these two diseases. Our objective was to assess and compare for ventilator weaning modalities between patients mechanically ventilated for Guillain-Barré syndrome or for myasthenia gravis in a large-scale multicenter study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07022028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myasthenia Gravis
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07217587 — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis · Phase 3 · recruiting
- NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
- NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
- NCT07246564 — Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni · Phase 4 · recruiting
Other Poitiers University Hospital trials
Trials by the same sponsor.
- NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
- NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
- NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
- NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
- NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07022028 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
- Last refreshed: 18 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07022028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing